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Decreasing mortality and hospitalizations
with rising costs related to gastric cancer in
the USA: an epidemiological perspective
Delong Liu1,2* , Dhruv Mehta2†, Supreet Kaur3†, Arun Kumar2, Kaushal Parikh2, Lavneet Chawla2, Shanti Patel4,
Amirta Devi5 and Aparna Saha6
Abstract
Background: There is no convincing data on the trends of hospitalizations, mortality, cost, and demographic
variations associated with inpatient admissions for gastric cancer in the USA. The aim of this study was to use a
national database of US hospitals to evaluate the trends associated with gastric cancer.
Methods: We analyzed the National Inpatient Sample (NIS) database for all patients in whom gastric cancer (ICD-9
code: 151.0, 151.1, 151.2, 151.3, 151.4, 151.5, 151.6, 151.8, 151.9) was the principal discharge diagnosis during the period,
2003–2014. The NIS is the largest publicly available all-payer inpatient care database in the US. It contains data from
approximately eight million hospital stays each year. The statistical significance of the difference in the number of
hospital discharges, length of stay, and hospital costs over the study period was determined by regression analysis.
Results: In 2003, there were 23,921 admissions with a principal discharge diagnosis of gastric cancer as compared to
21,540 in 2014 (P < 0.01). The mean length of stay for gastric cancer decreased by 17% between 2003 and 2014 from
10.9 days to 8.95 days (P < 0.01). However, during this period, the mean hospital charges increased significantly by 21%
from $ 75,341 per patient in 2003 to $ 91,385 per patient in 2014 (P < 0.001). There was a more significant reduction in
mortality over a period of 11 years from 2428 (10.15%) in 2003 to 1345 (6.24%) in 2014 (P < 0.01). The aggregate
charges (i.e., “national bill”) for gastric cancer increased significantly from 1.79 bn $ to 1. 96 bn $ (P < 0.001), despite
decrease in hospitalization (inflation adjusted).
Conclusion: Although the number of inpatient admissions for gastric cancer have decreased over the past decade, the
healthcare burden and cost related to it has increased significantly. Inpatient mortality is decreasing which is consistent
with overall decrease in gastric cancer-related deaths. Cost increase associated with gastric cancer contributed
significantly to the national healthcare bill.
Keywords: Inpatient admission rates, Gastric cancer, Epidemiology, National inpatient database
Introduction
According to the World Health Organization (WHO)
International agency for research on cancer, approximately
one million new cases of gastric cancer were reported in
2012, making it the fifth most common cancer in the
world, after lung, breast, colorectal, and prostate cancer
[1]. Over the past few years, a steady decline is seen in
the age-adjusted gastric cancer incidence rate in the
developed countries including North America and Europe
[2–6]. These trends can be attributed in part to lifestyle
and hygiene changes such as a reduced consumption of
foods preserved by salting or smoking, and a reduction in
the prevalence of Helicobacter pylori (H. pylori) infection
[7, 8]. Gastric cancer carries a rather poor prognosis, with
cohort and period estimate of 5-year relative survival rate
below 25% [9, 10]. The most common treatment option
for gastric cancers is surgery with or without perioperative
chemotherapy for localized disease and chemotherapy
alone for metastatic disease. Immune checkpoint inhibitors
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have been approved for treatment of several solid tumors
and recently become a major option for gastric cancer ther-
apy [11–16]. Cancer immunotherapy including chimeric
antigen receptor T cells and bispecific antibodies are rapidly
changing the landscape of therapeutic approaches for solid
tumors including gastric cancers [17–24].
Despite a decline in gastric cancer incidence, it remains
one of the most common causes of cancer-related morbidity
and mortality and has a significant impact on the
United States (US) healthcare system [25, 26]. To the
best of our knowledge, there are no reported studies to
assess the demographic variations and trends of inpatient
hospitalization in gastric cancer in the US population.
This study is conducted to delineate the inpatient trends
of hospitalization, mortality, length of stay, cost, and
demographic variations of gastric cancer-related admis-
sions in the USA from the period of 2003 to 2014. The
study found that the number of inpatient admissions for
gastric cancer has decreased over the past decade, though
the healthcare burden and cost related to it have increased
significantly. Inpatient mortality is decreasing which is
consistent with overall decrease in gastric cancer-related
deaths.
Research design and methods
Research database
We obtained a population-based estimate of inpatient
hospitalization utilizing National Inpatient Sample (NIS),
developed by the agency for Healthcare Research and Qual-
ity (AHRQ, Rockville, Maryland), as a part of Healthcare
Cost and Utilization Project (HCUP) through a Federal-Sta-
te-Industry partnership. The details of this database has
been described [27, 28].
The NIS contains approximately 20% stratified sample
of discharges from community (non-federal) hospitals
and is the largest publicly available all-payer inpatient
health care data set in the USA. The 2003 NIS data were
selected using a stratified probability sample of hospitals,
drawn from a frame of 37 states containing approximately
8.0 million discharges from 994 hospitals, with weights to
facilitate national estimates. The 2014 NIS sampling frame
is obtained from more than 4400 hospitals in 44 states and
the District of Columbia and contains approximately seven
million discharges. The NIS is an excellent representative
sample of the general US inpatient population, representing
> 95% of the US population and provides a comprehensive
database for analyzing healthcare utilization, access,
charges, quality, and outcomes. This database provides
only administrative data for analysis. Patient-specific
clinical data is lacking.
We identified cases of gastric cancer by querying the
NIS database for hospital data on all discharge diagnoses
with a primary ICD-9 CM diagnosis code of 151 (151.0,
151.1, 151.2, 151.3, 151.4, 151.5, 151.6, 151.8, 151.9)
from 2003 to 2014.
Patients and hospitals
Patient demographics, including age, sex, and insurance
status, was obtained from the NIS database. Various
hospital characteristics, including location (Northeast,
Midwest, South and West and metropolitan vs non-
metropolitan area), type (teaching vs non-teaching), and size
(small, medium, and large) were recorded. Metropolitan
areas were defined as those with a population of at least
50,000 people. A teaching hospital was defined as one
designated as an American Medical Association (AMA)-
approved residency program by the American Hospital
Association Annual Survey, a member of the Council of
Teaching Hospitals or has a ratio of full-time equivalent
interns and residents to beds of 0.25 or higher. The defin-
ition of bed-size varied according to hospital location and
teaching status and hence there is a large overlap in the
definition of hospital size. For small hospitals, bed-size
ranged from 1 to 299 beds, for medium hospitals the
range was between 50 and 499, and for large hospitals it
was between 100 and 500 beds or higher (Appendix). We
also obtained the payer status for all admissions. “Length
of stay” was defined as the number of nights the patient
remained in the hospital for this inpatient visit.
Statistical analysis
The trends for the annual point estimates of frequency of
gastric cancer for the sample were analyzed. The annual
frequency of discharges with a diagnosis of gastric cancer
was computed by dividing the annual number of dis-
charges with gastric cancer listed in the NIS database
in each year by the total number of all discharges listed
in the NIS for the same year. The temporal trend in fre-
quencies of discharges, lengths of stay, hospital charges,
and frequencies of deaths in patients with gastric cancer
was estimated by linear and polynomial regression. The
most appropriate functional form for the trend was
assessed by examination of regression diagnostic plots.
Linear shape was determined for hospital charges and
in-hospital deaths: a quadratic shape for length of stay and
a cubic shape for number of discharges and discharge rate.
A P value < 0.05 was considered statistically significant.
All analyses were performed using SAS (version 9.4, The
SAS Institute, Cary, NC).
In addition to the percentages available adjacent to the
data in the tables, the frequency per 10,000 admissions
were also calculated for each categorical variable. These
numbers represent the density of patients diagnosed
with gastric cancer compared with the total number of
hospital discharges per category. Each frequency was
calculated by dividing the number of patients with a
diagnosis of gastric cancer by the total discharges in a
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specific categorical variable for each year and multiplying
that number by 10,000. We viewed the counts as arising
from a Poisson distribution and the total discharges as an
offset, yielding Poisson rates that were compared over
time using Poisson regression and yielded relative rates
(RRs) and 95% confidence intervals (CIs) that expressed
the ratio of rate per 10,000 in 2014 to that of 2003. These
values differed from the percentages, which describe each
category exclusively for either patients with gastric cancer
or for total discharges. The percentages distinguished
differences among the variables for each specific year,
whereas the frequencies were vital for comparing trends
from 2003 to 2014, especially for age group and region.
Results
Number and costs of gastric cancer discharges
The absolute number of admissions for gastric cancer as
the primary diagnosis showed a decreasing trend from
23,921 in 2003 to 21,540 in 2014 (P < 0.01). Expectedly,
discharges with gastric cancer also decreased from 6.45 per
10,000 discharges in 2003 to 6.09 per 10,000 discharges in
2014 (RR 0.94, 95% CI 0.92–0.96, P < 0.0001) (Fig. 1).
The average length of hospital stay for patients with
gastric cancer as a principal diagnosis decreased from
10.9 days in 2003 to 8.95 days in 2014 (P < 0.01). Despite
the decrease in the average length of hospital stay, the
mean total charges for gastric cancer-related hospital
admissions showed a considerable increase between 2003
and 2014. After adjusting for inflation, mean hospital
charges per patient increased by 21.2% in a statistically
significant linear fashion from $75,341 in 2003 to $91,385
in 2014 (P < 0.001). The total aggregate cost “national
burden” for hospitalizations with gastric cancer as the
discharge diagnosis increased from $1.79 billion in 2003
to $1.96 billion in 2014 (inflation adjusted) (P < 0.001)
(Fig. 2).
Reduction in mortality
Although there was a slight decrease in the frequency
of hospital discharges from 2003 to 2014, there was a
more significant reduction in mortality over a period of
11 years from 10.15% in 2003 to 6.24% in 2014 (P < 0.01)
(Fig. 3).
Patient characteristics by age
The highest rate of discharges with the principal diagnosis
of gastric cancer was seen in age group of 65–84 years.
There was 12% decrease in the frequency of discharge
rates in the age group of 65–84 years from 12,420 in
2003 to 10,255 in 2014 (RR = 0.88 95% CI 0.86–0.90;
P < 0.0001). The frequency of discharge rates was very
similar in the age group of 45–64 years without any
statistical significance. The frequency of discharges showed
a decline from 9.6 per 10,000 admissions in 2003 to 6.6 per
10,000 admissions in 2014 in the + 85-age group (RR = .68,
95% CI 0.64–0.73, P < 0.0001). Interestingly, the only
group that showed an increment in the frequency of
hospitalization was the age group 18–44 years from
1.66 per 10,000 admissions in 2003 to 1.82 per 10,000
admissions in 2014 (RR = 1.1, 95% CI 1.02–1.17; P < 0.05)
(Table 1).
Patient characteristics by sex
The frequency of gastric cancer discharges was higher in
males; however, the decrease in the frequency of gastric
cancer-related hospitalization from 2003 to 2014 was
slightly more prominent in females. Male hospitalization
in both 2003 and 2014 were 2.4-folds higher than that of
Fig. 1 Trends of gastric cancer hospitalizations
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their female counterparts. The frequency of discharges
in men decreased from 9.9 per 10,000 admissions in 2003
to 9.3 per 10,000 admissions in 2014 (RR = 0.93, 95% CI
0.91–0.96; P < 0.0001). The frequency of discharges in
women decreased from 4.1 per 10,000 admissions in 2003
to 3.68 per 10,000 admissions in 2014 (RR = 0.89, 95% CI
0.87–0.92; P < 0.0001). (Table 1).
Patient characteristics by payer group and income
Between 2003 and 2014, the relative frequency of gastric
cancer discharges decreased for Medicare users and
increased for Medicaid and private insurers. In both 2003
and 2014, the highest absolute number of discharges were
noted in the Medicare group (56.6% in 2003 and 52.04%
in 2014). The decrease in the relative frequency of gastric
cancer discharges was seen to be greatest in Medicare
patients. The discharge rate decreased from 9.8 per 10,000
admissions in 2003 to 8.1 per 10,000 admissions in 2014
(RR = 0.82, 95% CI 0.80–0.84, P < 0.0001). Medicaid group
showed an increase in the relative frequency of discharges
by 20% from 2.8 per 10,000 admissions in 2003 to 3.47
per 10,000 admissions in 2014 (RR = 1.2, 95% CI 1.1–1.3;
P < 0.0001), followed by private insurance (5.17 per 10,000
in 2003 and 5.5 per 10,000 in 2014 with RR = 1.08) with
no changes observed in uninsured group.
Patients were categorized into low and not-low income
groups based on median income for zip code. In both
2003 and 2014, nearly 70% of the absolute number of
discharges were considered in the “not-low” income
group. Both groups showed similar decrement of around
7% in the number of discharges over the study period
(P < 0.01) (Table 1).
Fig. 2 Mean length of stay and cost of hospitalization
Fig. 3 Mortality trends in gastric cancer with hospitalization
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Patient discharges by hospital characteristics and region
During 2003 and 2014, metropolitan areas had higher
absolute number as well as frequency of gastric cancer
discharges than those from the non-metropolitan areas.
In metropolitan areas, the frequency of discharges
decreased from 6.9 per 10,000 in 2003 to 6.45 in 2014
(RR = 0.93, 95% CI 0.92–0.95, P < 0.0001). The frequency
of discharges in non-metropolitan areas showed a more
dramatic decrease from 4.2 per 10,000 to 2.7 per 10,000
(RR = 0.65, 95% CI 0.6–0.7, P < 0.0001).
Between 2003 and 2014, the relative frequency of gastric
cancer discharges decreased for small and medium size
hospitals and slightly increased for large size hospital
(P < 0.01). In both 2003 and 2014, the highest absolute
number of discharges were noted in the large size hospital
group (66.99% in 2003 and 60.79% in 2014).
The South had the highest number of gastric cancer
discharges during 2003 and 2014 (34.66% and 36% respect-
ively). The highest relative frequency of discharges was
seen in the west at 8 per 10,000 admissions in 2003 and
northeast with 7.3 per 10,000 admissions in 2014. The
change in the relative frequency of discharges for northeast
and midwest regions remained statistically insignificant
from 2003 to 2014. The frequency of discharges in the
south decreased from 5.8 per 10,000 in 2003 to 5.6 per
10,000 in 2014 (RR = 0.96, 95% CI 0.93–0.98; P < 0.05).
The frequency of discharges for the west showed a 20%
decrease in the rate of hospitalization from 8 per 10,000
in 2003 to 6.4 per 10,000 in 2014 (RR = 0.80, 95% CI
0.77–0.83; P < 0.001). (Table 1)
Discussion
We studied the trends of inpatient hospitalizations, mor-
tality, and costs in patients with gastric cancer during the
period from 2003 to 2014. We found a statistically signifi-
cant decline in gastric cancer hospitalizations during the
study period, which can be explained by an overall decline
in gastric cancer incidence and advances in outpatient
management of these patients, leading to fewer admis-
sions [29, 30]. H. pylori infection plays a central role in the
development of gastric cancer and a decline in incidence
rates of gastric cancer correlated to an overall decline in
and improved management of H. pylori infection [31, 32].
This trend may also be related to improvements in living
conditions, water supply, drainage, and better hygiene
related to food consumption [33]. Studies have shown an
increase in adoption of novel and evidence-based gastric
cancer therapies, such as endoscopic resection of early
cancer and use of adjuvant chemotherapy in locally
advanced disease which are associated with improved sur-
vival in early-stage cancers and can explain lesser numbers
of unplanned admissions [34]. With earlier and increasing
use of immune checkpoint inhibitors for therapy of gastric
cancer, further decline in admission and hospitalization
for gastric cancer is expected [34]. Future analysis of
discharge data from NIS will be able to provide evidence
on this.
Our study showed that the highest inpatient hospitali-
zations secondary to gastric cancer are seen in elderly
patients, which can be explained by the higher incidence
of gastric cancer in the elderly patients above age 65.
Elderly patients may often have comorbidities which in-
crease the 30-day postoperative mortality rates and
some of these patients may not be considered fit for
curative resection even in early disease secondary to
significant comorbidities [35]. Moreover, studies have also
shown that elderly patients often have a more advanced
stage of the non-cardia gastric cancers, a higher incidence
of cardia cancers, which are associated with a poor progno-
sis [36–38]. The major treatment option for the advanced
stages of gastric cancer used to be chemotherapy. The
palliative chemotherapy carries a poor response rate and
multiple complications secondary to therapy or the cancer,
such as gastrointestinal (GI) bleeding, gastric outlet/intes-
tinal obstruction, peritoneal carcinomatosis and intractable
vomiting, which result in poor quality of life and multiple
hospitalizations in these patients [39]. Interestingly, we
found there was a decrease in hospitalization trends in all
age groups except in younger patients age 18–44 years,
which showed an increment in inpatient admissions.
We postulate that the younger patients have lesser
number of comorbidities and are more amenable to curative
resections and early aggressive therapies requiring frequent
inpatient hospitalizations. There is an improved overall
survival in gastric cancers, especially in younger patients
[40]. However, we postulate that the morbidity associated
with gastric cancer including complications secondary to
chemotherapy and/or surgical interventions requires mul-
tiple hospitalizations. Overall, we found a decline in gastric
cancer-related hospitalizations in other age groups, which
coincides with an overall decline in gastric cancer incidence.
This study also found an increased number of discharges
from the metropolitan hospitals as compared to non-metro-
politan hospitals. This may be explained by a multidisciplin-
ary approach in the metropolitan hospitals towards the care
of the gastric cancer patients and early involvement of the
palliative care team, especially in patients with advanced dis-
ease, thus leading to decreased hospital mortality, better
quality of life, lesser number of hospitalizations, and higher
rates of discharges to hospice care [41]. Furthermore,
low socioeconomic status is one of the factors prevalent
in patients with gastric cancer, leading to the highest
number of admissions and discharges in the government
hospitals [42].
We also found a decline in gastric cancer-related inpatient
mortalities during the study period, which can be related to
the improved management of gastric cancers and overall
improved survival with the advent of more sophisticated
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surgical techniques and use of preoperative chemotherapies
[43]. Furthermore, the implementation of hospice care for
patients with advanced disease unamenable to aggressive
therapy has decreased the rate of inpatient hospitalizations
and overall inpatient deaths [44]. Terminal patients with
hospice care require less admissions to acute care wards and
intensive care units and have improved quality of life [45].
The average length of hospital stay has shortened
during the study period from 10.9 days in 2003 to 8.95 days
in 2014. It can be related to better management of
chemotherapy-related complications and more sophisti-
cated surgical techniques causing lesser complications
resulting in early discharges. However, we found a signifi-
cant increase in cost of hospitalizations with gastric cancer.
It is likely related to the (1) increasing overall cost of health
care, particularly the higher cost of targeted agents, (2)
cost of palliation- interventions for pain management
and palliative alleviation of symptoms, and (3) use of
palliative chemotherapy as standard of care in advance-
stage gastric cancer and costs associated with the manage-
ment of chemotherapy complications and morbidity
secondary to advanced cancer [46]. Per the NIS database,
the mean cost of all hospitalization increased by 16.2%
from 2003 to 2014 (9364$ to 10,885$ after adjusting for
inflation). With gastric cancer, an increase of about 21.2%
was noted during the same period. This can be attributed
to the increasing cost of hospitalization as well as more
health care dollar spent on gastric cancer care ($75,341 in
2003 to $91,385 in 2014).
Most patients with gastric cancer are elderly with access
to Medicare insurance, which explains the highest absolute
number of admissions in Medicare group. In general, we
found disparities in the gastric cancer hospitalization
depending upon insurance type. Uninsured patients or
patients with Medicare or Medicaid are known to have
lower odds of having recommended outpatient follow-ups
and receiving chemotherapy or radiation therapy, resulting
in higher incidence of emergency department visits and
hospitalizations [47]. Studies have also shown racial/ethnic
disparities seen in the use of evidence-based therapies in-
cluding preoperative chemotherapy and radiation therapy,
which result in disparities in overall survival and advanced
cancer and chemotherapy complications requiring multiple
hospitalizations [48]. We also found a significant difference
in gastric cancer-related hospitalizations secondary to
gender, with higher number of admissions in males
than females. This correlates with higher incidence of
gastric cancer in males [49]. While the mechanisms
leading to gender disparity are unconfirmed, studies
have linked genetic mutations in males, specifically
disruption of androgen receptor (AR) homeostasis, and
other lifestyle-related risk factors, such as higher con-
sumption of fried food and smoking, with development
of gastric cancer [49, 50].
NIS data set is purely administrative and is very
dependent on documentation and coding practices of
healthcare institutions and individual physicians. The
nature of the NIS data set and the study design are the first
and foremost limitations of our study. It is most likely that
our study underestimates the actual incidence of gastric
cancer-related hospitalizations, as patient admissions may
have been coded with other primary diagnosis such as
chemotherapy complications or complications of advanced
disease such as intestinal obstruction and GI bleeding.
Other possible limitations include any errors that may have
occurred during data entry and inability to obtain individ-
ual patient-specific clinical information, such as race/ethni-
city, laboratory values, and procedures performed, thereby
limiting observations to the given demographics of the
study sample. Lastly, NIS data set only provided limited
data regarding the hospital variables and does not provide
sufficient patient and hospital details to determine the
factors that could potentially explain the significant decline
in hospital discharges and a rise in cost of care.
In conclusion, gastric cancer-related hospitalizations and
mortality have declined over the last decade. However, it
remains a growing concern in the US healthcare system
secondary to an increase in health care costs and burden.
Despite a decline in gastric cancer-related hospitalization
and mortality, the overall cost of care continues to rise in
the last decade. Further studies are warranted on cost-ef-
fective evaluation and management of gastric cancer.
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Rural 1–49 50–99 100+
Urban, non-teaching 1–124 125–199 200+
Urban, teaching 1–249 250–424 425+
Midwest region
Rural 1–29 30–49 50+
Urban, non-teaching 1–74 75–174 175+
Urban, teaching 1–249 250–374 375+
Southern region
Rural 1–39 40–74 75+
Urban, non-teaching 1–99 100–199 200+
Urban, teaching 1–249 250–449 450+
Western region
Rural 1–24 25–44 45+
Urban, non-teaching 1–99 100–174 175+
Urban, teaching 1–199 200–324 325+
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